provide us results. an third once and of again Thank for today good as to time quarter you, highlights we Thank business you join overview XXXX recent and afternoon, taking our everyone. discuss financial
Joining for are will LaFrance, third regulatory a focus be Chief our turn our and LaFrance the to our the me Norman Officer. progress Financial with Andrew then review to Medical reviewing for and begin financials. I'll Q&A. call Mr. Andrew our quarter Dr. the clinical us the Chief Dr. on call call today Officer; over and then by Sims, recent joining
updates with or GBM. begin glioblastoma radiotherapeutic programs, recurrent on cancer lead I'll with starting our X CNS
Our to Phase end XXX XXXX. add patients sites substantially order GBM, funded work of enrollment Gap] Obisbemeda the the as new Rhenium ReSPECT-GBM [Audio trial with by to to in in II enroll GBM by the complete of we of
trial, to trial II parallel In the dose active the escalation I Phase Phase continues to enroll.
and large bigger size to safety. volumes tumors effects the in distribution, administered very of tumor radiation doses Assessing coverage radiation high on
the ReSPECT-GBM August. on at update in Neuro-Oncology an presented meeting Society We trial the for ASCO
and radiation across single Rhenium dose-limiting well administration with XXX systemic of Obisbemeda To exposure toxicities generally summarize tolerated patients. the data, is no XX GBM a safety minimal
with patients moderate due dose was experienced Most were to withdrew and of or not nonserious. patients death outcome no tolerated the addition, mild maximum reached. treatment-related and AEs. AEs adverse intensity The in events In no
presented overall tumor efficacy, at we highly In the discussed absorbed that survival treated set and With data the last volume. median tumor dose absorbed quarter, found radiation regard to XXX dose briefly is to SNO/ASCO, grade. with the we as correlated was
median I in patients absorbed When in less months. absorbed And median median overall Cohort survival X at about survival Phase almost months. for survival patients doses or or with greater gray, than X, overall XXX weeks we contrast XX the was the doses than XXX look XX through with XX overall trial was for weeks gray,
Cox we have each statistical found for the Applying of of the total in dose, of ratio can increase decreased for much in by to the website. XX.X% death volume, proportional This on model, gray total greater tumor found decreased the be XXX in our each absorbed that and treated by risk detail hazard increase risk data XX% XX.X%. death
continue we trial. addition, to the Phase assess ongoing II data In from
will presented Phase data New the safety be SNO and November. efficacy in II from at
event will soon, into and we well SNO to with invite details be as this meeting, is discuss trial data SNO a these deeply. and more feature hosting detail. We'll the This who as presenting opinion others. principal in the is delve sharing at of Brenner, of the you data neuro-oncology we data leader the will Dr. experts Following Andrew key webinar us expert, on join as be investigators investigator the a to webinar the
a funded substantially leptomeningeal trial This our Rhenium is of trial let escalation is that by metastases Now the of state through CPRIT. Phase dose LM. you for me on or update I/IIa with Obisbemeda Texas ReSPECT-LM patients
in enthusiasm in the in remains completed roll the X all enrollment to trial. meeting date Completing the the Cohort cohorts Following Phase high. Part in was QX, patients dosing Cohort from of X LM X of and trial. cohorts the a is FDA in rapidly sites first successful X of to participate fastest we the Type planned C Cohort I B
Prior August, further trial, past and results I meeting. following presented X. specifically to cohorts at roundtable context This of X the meeting, Part explanation FDA and August KOL through Phase meeting we the completed SNO/ASCO provided we event the the of these the A our cohorts at
cohorts, In summary, for least toxicities profile the single data a administration. remain space been drug for dose-limiting Pharmacokinetic shows the showed safety have throughout no the that CSF the following days X first and and at X favorable reached. rapidly analysis there circulated
tumor of XX And finally, tumor post-treatment at alive. Using of still days we XX%. with overall the an X average found cell of median survival CNSide that enumeration cell patients assay, XX XX months reduction counts was
CPRIT September. We data the at also presented cancer in innovations in LM
As be research received funding mentioned, advanced as we development $XX.X to by award. the X-year product of part in through a respect L&M the continues September, million funded payment $X.X contract. million planned Phase CPRIT In part I grant a program
for the of discuss will grant a Andrew years couple next the forecasted going revenue forward moment. in
our provide the LM the CNSide for cerebral even in state-of-the-art our spinal we evaluation. big the negotiated LM Taking treatment LM the I'll first. trial imaging, further of on license at of and monitoring diagnosis are with August. a and response in in The look Now difficult and some agreement assay clinical traditional fluid used assay evaluation the color picture notoriously
of care. CSF. cells highly mL improvement enumeration in of substantial technology is tumor of of as contrast, standard cell CSF quantitates to In This sensitive the compared number tumor a represents and that measure the assay CSF specific a assessing per cells CNSide a tumor
assay our although CNSide the initially value it paraphrase pretty firsthand diagnosis the of the endpoint, obviously our approach. skeptical At team secondary use on a disease And monitoring. to quite potential synergistic with is technology the in LM of seen LM of as therapeutic are and and for trial changer" therefore, has investigators, a our LM "game Plus, we it's value trial assay and one the our
the in the based utility it financial the the Biocept, The that been declared way to of though company's upon that quality this test, a was want distress financial assay, XXXX of clear and earlier not of company their in has on I throughout factors. the but developed distress variety insolvency month. make unrelated any
the all Plus completed CNSide from the per as of And successfully transfer prior use be begin However, and assay. trial it now can the no commercially very to to tumor announcement not cell where this enumeration patients. CSF ReSPECT-LM as Biocept's of proprietary Biocept now, to longer and plan, Plus materials limited our the concern, equipment test is available now us testing because to
which consider exercise closely. insolvency is license. whether exclusivity we In Separately, proceedings of to through monitor the we under exercisable option the the will XXXX we'll that end the meantime, have the current
trial. pending DSMB X quarter approval. to to back plan our We Cohort Now LM dosing initiate in this
step In planning we data continue ReSPECT-LM, for will focus to including enrollment, site of for steps, next onboarding, II. terms next Phase on assessment and
to trials. has progress make cancer in of our initiating required the trial. reasonable next pediatric from initiation behind is as our from brain had and follow-up ongoing terms within in us, we first-in-child pediatric satisfactorily our substantially data addressable positive supporting particularly meeting quarter. all In schedule more the are continue FDA and our Trial We QX, steady a trial, requests original both FDA
Lurie in with pending the Hospital plan brain early anticipated trial be pediatric pediatric at the in patients and I ependymoma clearance initiate Chicago. glioma Phase to Thereafter, from Children's cancer high-grade FDA ReSPECT to XXXX, for we IND the
make Rhenium-XXX continues development regulatory Our other microsphere or radiotherapeutic novel progress. alginate BAM biodegradable NanoLiposome for to short,
time to received tumors. a a treat a is regulatory embolic reminder, radioembolization recently its We solid product from requirements in good regarding be and the as the designed are as this regulated variety line compound a As designation of in for be paths BAM reduced already organ CDRH. place. will very primarily feedback and as radio BAM FDA the news existing by device, clinical will We approval view reimbursement
FDA goals decision. the FDA based include will BAM guidance Our XXXX for corporate regulatory development for specific -- on
including of isotope the shore production, as to supply across-the-board to expand supply scenes, in terms agreements drug chain and in behind it relates to Now continue build up availability. existing work we and redundancy,
complete agreements or will new those. we relationships, we As communicate
now with Chief will Andrew Financial the who turn financials. over Andrew? And our Sims, the that, Officer, review I'll call to
